AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32000786 — intervention group
Group type: EXPERIMENTAL
Intervention: House characteristics
Number of subjects: 467
Study 33120756 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture Deqi group
Number of subjects: 300
Study 33120756 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture without Deqi group
Number of subjects: 300
Study 33120756 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 300
Study 36273360 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP + cataract surgery (Group 1)
Number of subjects: 0
Study 36273360 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP + cataract surgery + iStent inject (Group 2)
Number of subjects: 0
Study 36273360 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study 33675343 — intervention group
Group type: COMPARATOR
Intervention: Non-interesterified fat (non-IE)
Number of subjects: 20
Study 33675343 — intervention group
Group type: COMPARATOR
Intervention: Interesterified fat (IE)
Number of subjects: 20
Study 32141365 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive music therapy during catheter placement and post-procedure (30-45 min during placement, twice a day for 30 min until discharge)
Number of subjects: 304
Study 32141365 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 304
Study 35084480 — intervention group
Group type: EXPERIMENTAL
Intervention: Plinabulin, 40 mg
Number of subjects: 105
Study 35084480 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim, 6 mg
Number of subjects: 105
Study 33731209 — intervention group
Group type: EXPERIMENTAL
Intervention: GV-971 (900 mg)
Number of subjects: 818
Study 33731209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 818
Study 36088650 — intervention group
Group type: COMPARATOR
Intervention: GSK2831781 450 mg IV
Number of subjects: 0
Study 36088650 — intervention group
Group type: COMPARATOR
Intervention: GSK2831781 150 mg SC
Number of subjects: 0
Study 36088650 — intervention group
Group type: COMPARATOR
Intervention: GSK2831781 450 mg SC
Number of subjects: 0
Study 36088650 — intervention group
Group type: COMPARATOR
Intervention: Placebo IV
Number of subjects: 0
Study 36088650 — intervention group
Group type: COMPARATOR
Intervention: Placebo SC
Number of subjects: 0
Study 36088650 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2831781 (IV and SC)
Number of subjects: 0
Study 32457083 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated FMT
Number of subjects: 80
Study 32457083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33453140 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)
Number of subjects: 43
Study 33453140 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 43
Study 32088993 — intervention group
Group type: EXPERIMENTAL
Intervention: WM-targeted cognitive remediation program (25 sessions of 30-40 minutes over 5 weeks)
Number of subjects: 28
Study 32088993 — intervention group
Group type: EXPERIMENTAL
Intervention: WM-targeted cognitive remediation program
Number of subjects: 28
Study 33485464 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg intravenously once every 2 weeks) plus ipilimumab (1 mg/kg intravenously once every 6 weeks) for up to 2 years
Number of subjects: 605
Study 33485464 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed [500 mg/m2 intravenously] plus cisplatin [75 mg/m2 intravenously] or carboplatin [area under the concentration‐time curve 5 mg/mL per min intravenously]) once every 3 weeks for up to six cycles
Number of subjects: 605
Study 32811682 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 47
Study 32811682 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib
Number of subjects: 47
Study 32811682 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 47
Study 32811682 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitors overall
Number of subjects: 47
Study 34382454 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital disease management platform (hybrid mHealth model integrating remote patient monitoring and applied health technology)
Number of subjects: 45
Study 34382454 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 45
Study 33128473 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% LT-BOL cream
Number of subjects: 21
Study 36220980 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha (DA)
Number of subjects: 50
Study 36220980 — intervention group
Group type: COMPARATOR
Intervention: recombinant human erythropoietin (rHuEPO)
Number of subjects: 50
Study 33704494 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs)
Number of subjects: 1320
Study 33704494 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid (IFA)
Number of subjects: 1320
Study 33704494 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrients (MMN)
Number of subjects: 1320
Study 33704494 — intervention group
Group type: EXPERIMENTAL
Intervention: High diastolic blood pressure (DBP)
Number of subjects: 1320
Study 33704494 — intervention group
Group type: EXPERIMENTAL
Intervention: High systolic blood pressure (SBP)
Number of subjects: 1320
Study 35923425 — intervention group
Group type: EXPERIMENTAL
Intervention: B-EV71 vaccine (Older-B group)
Number of subjects: 1600
Study 35923425 — intervention group
Group type: COMPARATOR
Intervention: C-EV71 vaccine (Older-C group)
Number of subjects: 1600
Study 35923425 — intervention group
Group type: EXPERIMENTAL
Intervention: B-EV71 vaccine (Younger-B group)
Number of subjects: 1600
Study 35923425 — intervention group
Group type: EXPERIMENTAL
Intervention: Older-B group
Number of subjects: 1600
Study 32790955 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 0
Study 32790955 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (CPT)
Number of subjects: 0
Study 36058697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower abdomen group
Number of subjects: 60
Study 36058697 — intervention group
Group type: COMPARATOR
Intervention: Lateral abdomen group
Number of subjects: 60
Study 34571023 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS stimulants
Number of subjects: 230
Study 36176768 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise (IHG) - 4 × 2 min at 30% of maximal voluntary contraction (MVC) with 1 min rest between sets, unilateral
Number of subjects: 0
Study 36176768 — intervention group
Group type: COMPARATOR
Intervention: Sham group - protocol at 0.3% of MVC
Number of subjects: 0
Study 36176768 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise (IHG)
Number of subjects: 0
Study 36176768 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 0
Study 33037632 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 743
Study 33037632 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 743
Study 34478604 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic tape (TVT, GYNECARE™)
Number of subjects: 180
Study 34478604 — intervention group
Group type: COMPARATOR
Intervention: Transobturator tape (TOT, MONARC™)
Number of subjects: 180
Study 34478604 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TVT and TOT
Number of subjects: 180
Study 32342857 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml/kg/day feed increments
Number of subjects: 2804
Study 32342857 — intervention group
Group type: COMPARATOR
Intervention: 18 ml/kg/day feed increments
Number of subjects: 2804
Study 35403244 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOF Lipid Emulsion (SMOF‐LE)
Number of subjects: 528
Study 35403244 — intervention group
Group type: COMPARATOR
Intervention: Non-SMOF Lipid Emulsion (non‐SMOF‐LE)
Number of subjects: 528
Study 32210340 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 109
Study 32210340 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 109
Study 32210340 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 109
Study 35299968 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, Bifidobacterium animalis subsp. lactis CP-9) administered daily for 6 months along with regular insulin therapy.
Number of subjects: 56
Study 35299968 — intervention group
Group type: COMPARATOR
Intervention: Control group (insulin therapy without probiotics).
Number of subjects: 56
Study 35299968 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics intervention.
Number of subjects: 56
Study 33300212 — intervention group
Group type: EXPERIMENTAL
Intervention: semi‐elevated right lateral position
Number of subjects: 34
Study 33300212 — intervention group
Group type: COMPARATOR
Intervention: semi‐elevated supine position
Number of subjects: 34
Study 33235307 — intervention group
Group type: EXPERIMENTAL
Intervention: Vype ePen3 with greater aerosol mass delivery
Number of subjects: 24
Study 33235307 — intervention group
Group type: EXPERIMENTAL
Intervention: Protonated nicotine (18 mg/mL, medium protonation) e-liquid
Number of subjects: 24
Study 33235307 — intervention group
Group type: COMPARATOR
Intervention: Nicotine benzoate formulation (30 mg/mL nicotine, high protonation)
Number of subjects: 24
Study 33704372 — intervention group
Group type: EXPERIMENTAL
Intervention: MRCIP (Mendelian randomization method)
Number of subjects: 0
Study 32166538 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil/Latanoprost FDC (0.02%/0.005%)
Number of subjects: 1468
Study 32166538 — intervention group
Group type: COMPARATOR
Intervention: Netarsudil (0.02%)
Number of subjects: 1468
Study 32166538 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost (0.005%)
Number of subjects: 1468
Study 36226244 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX and LEF combination therapy
Number of subjects: 120
Study 36226244 — intervention group
Group type: COMPARATOR
Intervention: MTX only (Control)
Number of subjects: 120
Study 34543098 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg daily dose of linezolid
Number of subjects: 124
Study 34543098 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg daily dose of linezolid
Number of subjects: 124
Study 36190041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular viscoelastic device (OVD) group
Number of subjects: 70
Study 36190041 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 36190041 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 33814474 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG BF training combined with conventional physical therapy (n=17)
Number of subjects: 33
Study 33814474 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (Control group, n=16)
Number of subjects: 33
Study 32807615 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage lateral thoracodorsal flap with an implant
Number of subjects: 0
Study 32807615 — intervention group
Group type: COMPARATOR
Intervention: Two-stage expander reconstruction
Number of subjects: 0
Study 32807615 — intervention group
Group type: EXPERIMENTAL
Intervention: Latissimus dorsi reconstruction combined with an implant
Number of subjects: 0
Study 32807615 — intervention group
Group type: COMPARATOR
Intervention: Deep inferior epigastric artery perforator (DIEP) reconstruction
Number of subjects: 0
Study 32880468 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy or chemoradiotherapy
Number of subjects: 2173
Study 32880468 — intervention group
Group type: COMPARATOR
Intervention: Standard pathological evaluation according to the Leeds protocol
Number of subjects: 2173
Study 32880468 — intervention group
Group type: COMPARATOR
Intervention: Up-front resection with adjuvant chemotherapy
Number of subjects: 2173
Study 33026636 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 18
Study 33047216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemdisiran (50–900 mg single doses or 100–600 mg repeat doses)
Number of subjects: 32
Study 33047216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemdisiran (200 or 400 mg weekly)
Number of subjects: 32
Study 33047216 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab (900 or 1200 mg biweekly)
Number of subjects: 32
Study 33047216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemdisiran (600 mg)
Number of subjects: 32
Study 33047216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemdisiran (various doses)
Number of subjects: 32
Study 33394852 — intervention group
Group type: EXPERIMENTAL
Intervention: Paxos Scope (smartphone-based ophthalmic camera)
Number of subjects: 467
Study 32393307 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus the offer of an additional preventive care consultation with the specialist clinician (occupational therapist)
Number of subjects: 0
Study 32393307 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 36116675 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric conditioning (GC) before surgery
Number of subjects: 38
Study 36116675 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful gastric conditioning (GC)
Number of subjects: 38
Study 33885775 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (800 mg loading dose, then 400 mg daily for 9 days)
Number of subjects: 685
Study 33885775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (800 mg and 200 mg loading dose every 12 hours, followed by 400 mg and 100 mg every 12 hours for 9 days)
Number of subjects: 685
Study 33885775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 685
Study 33885775 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 685
Study 33885775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir
Number of subjects: 685
Study 34505548 — intervention group
Group type: EXPERIMENTAL
Intervention: Device dropper (DD) method
Number of subjects: 72
Study 34505548 — intervention group
Group type: COMPARATOR
Intervention: Conventional drop instillation (CDI) method
Number of subjects: 72
Study 33504185 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Number of subjects: 259
Study 33504185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 35940954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculus GO VR goggles
Number of subjects: 29
Study 35940954 — intervention group
Group type: COMPARATOR
Intervention: No VR goggles
Number of subjects: 29
Study 33907242 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum alpha‐klotho concentration
Number of subjects: 103
Study 32452588 — intervention group
Group type: EXPERIMENTAL
Intervention: PBI-05204
Number of subjects: 42
Study 33866856 — intervention group
Group type: EXPERIMENTAL
Intervention: Top 3 cost categories
Number of subjects: 0
Study 33866856 — intervention group
Group type: EXPERIMENTAL
Intervention: Top 5 cost categories
Number of subjects: 0
Study 33866856 — intervention group
Group type: EXPERIMENTAL
Intervention: All cost components
Number of subjects: 0
Study 33866856 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapies
Number of subjects: 0
Study 33012605 — intervention group
Group type: EXPERIMENTAL
Intervention: BK-SE36/CpG (full-dose)
Number of subjects: 26
Study 33012605 — intervention group
Group type: EXPERIMENTAL
Intervention: BK-SE36/CpG (half-dose)
Number of subjects: 26
Study 33012605 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 26
Study 33032885 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger Kazoo Intensive Short-Term Vocal Therapy
Number of subjects: 24
Study 33032885 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 32258112 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 46
Study 32258112 — intervention group
Group type: COMPARATOR
Intervention: Control (wellness education program)
Number of subjects: 46
Study 34797597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of tranexamic acid
Number of subjects: 43
Study 34797597 — intervention group
Group type: COMPARATOR
Intervention: Topical application of Kligman combination drug
Number of subjects: 43
Study 34548284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (mean HbA1c 7.2%)
Number of subjects: 0
Study 34548284 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (mean HbA1c 9.0%)
Number of subjects: 0
Study 34548284 — intervention group
Group type: EXPERIMENTAL
Intervention: DCCT intensive therapy
Number of subjects: 0
Study 34548284 — intervention group
Group type: COMPARATOR
Intervention: DCCT conventional therapy
Number of subjects: 0
Study 33964415 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation trial participants who smoked >1 pack per day
Number of subjects: 926
Study 33964415 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation trial participants who underwent their first LCS scan
Number of subjects: 926
Study 33964415 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation trial participants with an associates degree
Number of subjects: 926
Study 33964415 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation trial participants with a bachelor's degree
Number of subjects: 926
Study 33964415 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation trial participants with some worry about lung cancer
Number of subjects: 926
Study 33964415 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation trial participants with a benign screening result
Number of subjects: 926
Study 33964415 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation trial participants with a probably benign screening result
Number of subjects: 926
Study 36416841 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 international units daily)
Number of subjects: 2083
Study 36416841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2083
Study 33360047 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g/day)
Number of subjects: 160
Study 33360047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 32993628 — intervention group
Group type: EXPERIMENTAL
Intervention: Education reinforcing practice guidelines with manufacturer-prepared pre-filled flush syringes.
Number of subjects: 619
Study 32993628 — intervention group
Group type: COMPARATOR
Intervention: Standard care with manually prepared flushes of 0.9% sodium chloride (control group).
Number of subjects: 619
Study 32993628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (education and guidelines).
Number of subjects: 619
Study 36161344 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (700 IU) plus Calcium (500 mg) daily for 3 years
Number of subjects: 386
Study 36161344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double placebo) daily for 3 years
Number of subjects: 386
Study 34628916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting and lying Liuzijue exercise (LG) for 3 months, 30 minutes twice daily.
Number of subjects: 80
Study 34628916 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment and nursing (CG)
Number of subjects: 80
Study 32059477 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous, self-monitored, lifestyle modification program (intervention group, IG) for 12 months
Number of subjects: 300
Study 32059477 — intervention group
Group type: COMPARATOR
Intervention: General advice (GA)
Number of subjects: 300
Study 35689818 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulphate tablets (OST)
Number of subjects: 110
Study 35896217 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4-mm cryoprobe
Number of subjects: 89
Study 35896217 — intervention group
Group type: COMPARATOR
Intervention: 1.9-mm cryoprobe
Number of subjects: 89
Study 35896217 — intervention group
Group type: COMPARATOR
Intervention: Forceps
Number of subjects: 89
Study 33849367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D, 1 μg/kg before, and 0.6 μg/kg/hour during procedure)
Number of subjects: 197
Study 33849367 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (Group M, 2 mg before procedure)
Number of subjects: 197
Study 32960773 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital devices for information delivery (tablet computers, e-learning platforms, public website)
Number of subjects: 0
Study 32960773 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital devices for information delivery
Number of subjects: 0
Study 34032356 — intervention group
Group type: EXPERIMENTAL
Intervention: Experts by Experience participation in mental health nursing education
Number of subjects: 0
Study 36437019 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-reduction programs for children engaging families and teachers
Number of subjects: 0
Study 36437019 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational song with interesting sounds and lyrics as BGM
Number of subjects: 0
Study 36437019 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of salt intake using a versatile salinity meter
Number of subjects: 0
Study 36437019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education for the elderly over three months
Number of subjects: 0
Study 33231313 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE)
Number of subjects: 6
Study 35480138 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab, gemcitabine, and cisplatin
Number of subjects: 100
Study 35480138 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine combined with cisplatin
Number of subjects: 100
Study 35328977 — intervention group
Group type: EXPERIMENTAL
Intervention: VR FestLab (intervention group)
Number of subjects: 372
Study 35328977 — intervention group
Group type: COMPARATOR
Intervention: Oculus Quest—First Steps (control group)
Number of subjects: 372
Study 34852983 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for risk of seizure recurrence
Number of subjects: 0
Study 34852983 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for risk of seizure recurrence (recalibrated)
Number of subjects: 0